Inbox14
Synced Nov 12 11:45 ET PHPreHealth
Agency workspace
Reports

Monthly listening brief

Conexeu Sciences Inc. · Nasdaq: CNXU · October 13, 2026 to November 12, 2026. Generated from the snapshots dated below; nothing in it is typed in.

Google News Nov 12 · conexeu.com crawl Nov 12 · PubMed Nov 12 · ClinicalTrials.gov Nov 12 · openFDA Nov 12

Key takeaway

Conexeu Sciences had 13 headlines in the 30 days to Nov 12 (2 the 30 days before), 12% share of voice against the Ring 1 analogs. 5 category topics are trending, led by Breast reconstruction beyond implants. 27 claims passages on conexeu.com still need review.

Supporting data
  • 13 headlines naming Conexeu (2 the 30 days before)
  • 12% share of voice vs Ring 1 analogs (4% before)
  • 5/6 category topics trending
  • 27 claims passages to review on conexeu.com
What we’re doing

First on the plan: Write a post on Regenerate, don't replace.

Key wins

Listed only when the data shows them.

  • Conexeu Sciences headlines rose to 13 in 30 days, from 2 the 30 days before.
  • Share of voice against the Ring 1 analogs rose to 12%, from 4%.
  • Most visible coverage: “Top Conexeu Sciences (CNXU) Competitors 2026” (MarketBeat, Nov 11).
  • conexeu.com declares Organization structured data, so answer engines can resolve the company as an entity.

Key opportunities

From trending topics, unowned target queries, new research and site gaps.

  • Breast reconstruction beyond implants is trending (24 headlines in 3 weeks, 1.5× its earlier pace). Angle open to Conexeu Sciences: Regenerate, don't replace.
  • Extracellular matrix and scaffolds is trending (10 headlines in 3 weeks, 3.3× its earlier pace). Angle open to Conexeu Sciences: what an ECM scaffold is, in plain language.
  • “Filler vs biostimulator vs scaffold” has no clear owner today (AI + Instagram search). The three-way comparison does not exist yet. Cleanest unclaimed query.
  • 33 new papers in the tracked research lanes; the newest, “In situ ECM-functionalized hyaluronic acid/dextran composite hydrogels for regenerative soft tissue reconstruction.”, can carry an unbranded clinician explainer.

1Coverage & share of voice

Key takeaway

Conexeu Sciences ranked tied #8 of 14 tracked brands by headlines in 30 days, with 13 headlines against 2 the month before. Most visible: “Top Conexeu Sciences (CNXU) Competitors 2026”.

Supporting data
  • 13 headlines in 30 days · 2 the 30 days before
  • 12% share of voice vs Ring 1 analogs · 4% before
  • 5.9% share of all tracked-brand headlines · 1.9% before
  • Top publishers: MarketBeat (2), Simply Wall St (2), Yahoo! Finance Canada (1), TradingView (1), Stock Titan (1)
  • By type: Markets 5, Funding 4, News 2, Product 1, Regulatory 1
Headlines naming Conexeu, newest firstPublisherDate
Conexeu Sciences Inc. (CNXU) Stock Price, News, Quote & HistoryYahoo! Finance CanadaNov 11Top Conexeu Sciences (CNXU) Competitors 2026MarketBeatNov 11Conexeu Sciences Launches Human Collagen Initiative For Regenerative Aesthetics As GLP-1 Drives Demand For Tissue RestorationTradingViewNov 10Consulting services were paid in $21,645 of stock by Conexeu Sciences (CNXU).Stock TitanNov 5Conexeu Sciences Independent Director Acquires 5.6% More StockSimply Wall StOct 21Conexeu Sciences completes $4 million private placement and issues unregistered sharesInvesting.comOct 20

2Category topics

Key takeaway

Breast reconstruction beyond implants and Extracellular matrix and scaffolds and Flowable wound matrices and 510(k) and Biostimulators and regenerative aesthetics and Dermal filler safety and regulation are moving faster than usual: the conversations Conexeu Sciences can join without a product claim.

Supporting data
  • 5 of 6 topics trending (≥3 headlines in 3 weeks at ≥1.25×)
  • 197 topic headlines in 90 days
Topic and the angle open to us3 weeksMomentum90 days
Breast reconstruction beyond implants
Regenerate, don't replace 24 1.5× 76
GLP-1 skin and volume loss
the structural argument: GLP-1 loss is architecture, not just volume 10 0.9× 46
Extracellular matrix and scaffolds
what an ECM scaffold is, in plain language 10 3.3× 20
Flowable wound matrices and 510(k)
the wound-care path and what a 510(k) does and does not mean 8 1.7× 22
Biostimulators and regenerative aesthetics
occupy, provoke, structure: the three mechanism classes 5 2.1× 13
Dermal filler safety and regulation
why structure, not volume, is the conversation to have 5 1.3× 20

3Competitors

Key takeaway

Establishment Labs carried the most competitor coverage (27 headlines in 30 days). Establishment Labs added the most: 27 against 6. Organogenesis and CollPlant and Allergan Aesthetics are running at 18.3× and 2.8× and 2.5× their usual week.

Supporting data
  • 13 competitors tracked across 3 rings
  • 209 competitor headlines in 30 days · 106 before
  • 3 at ≥2× their usual week with ≥2 headlines in 7 days
CompetitorRing30 daysBeforeVelocity
Establishment Labs
Breast aesthetics and reconstruction Narrative peers 27 6 1.5×
Evolus
Aesthetics: Jeuveau, Evolysse Category owners 26 14 1.4×
Integra LifeSciences
Wound care, flowable Structural analogs 25 30 1.4×
Galderma
Aesthetics: Sculptra, Restylane Category owners 24 12 1.4×
MiMedx
Wound care biologics Structural analogs 23 5 1.7×
Organogenesis
Advanced wound care Structural analogs 23 5 18.3×
CollPlant
Recombinant collagen, bioprinted breast implants Narrative peers 22 11 2.8×
Aroa Biosurgery
ECM bioscaffolds Structural analogs 13 6 1.1×

4Website & compliance

Key takeaway

27 passages on conexeu.com match a claims-scan rule, across 62 pages. Each is a passage to review with client counsel, not a confirmed violation. 6 site basics also need fixing.

Supporting data
  • 62 pages crawled on Nov 12
  • 3 outcome verb (R1)
  • 3 approval language (R1/R6)
  • 21 uncaveated superlative (R7)
  • 62 of 62 pages carry the status line
  • 0 pages share a meta description · 2 with several H1s · 3 without a canonical
  • Organization schema present · llms.txt served

Every passage, with the pages it appears on, is on Compliance. The status line that travels with every claim: “CXU is an investigational medical device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established.”

5Science & FDA

Key takeaway

33 new papers in the tracked research lanes in the last 60 days. FDA issued 3 comparable 510(k) decisions in 6 months, the latest for Accelagen Advanced Surgical Collagen Matrix, 1cc (CG-01AA); Accelagen Advanced Surgical Collagen Matrix, 2cc (CG-02AA); Accelagen Advanced Surgical Collagen Matrix, 3cc (CG-03AA); Accelagen Advanced Surgical Collagen Matrix, 5cc (CG-05AA); Accelagen Advanced Surgical Collagen Strip, 125x25x2mm (CG-125X25AA); Accelagen Advanced Surgical Collagen Strip, 250x25x2mm (CG-250X25AA) (Berkeley Advanced Biomaterials). Conexeu Sciences’s 510(k) premarket notification, lead wound-care candidate: Planned Q1 2027.

Supporting data
  • 0 PubMed papers in 12 months · Ghahary lab (UBC) collagen papers
  • 139 PubMed papers in 12 months · ECM in regenerative aesthetics
  • 164 PubMed papers in 12 months · Flowable collagen in wound care
  • 74 PubMed papers in 12 months · GLP-1 and facial soft tissue
  • 160 studies on ClinicalTrials.gov · Flowable and injectable wound matrices
  • 78 studies on ClinicalTrials.gov · ECM and collagen fillers in aesthetics
  • 14 studies on ClinicalTrials.gov · Regenerative breast reconstruction
  • 11 510(k) decisions in 3 years · Collagen wound dressings and flowable matrices
Newest papers and 510(k) decisionsSourceDate
In situ ECM-functionalized hyaluronic acid/dextran composite hydrogels for regenerative soft tissue reconstruction.Biomater Adv · PubMed 42887182February 1, 2027Obesity, Weight Loss, and Facial Plastic Surgery.Otolaryngol Clin North Am · PubMed 42869738February 1, 2027Bariatric Surgery, Medical Weight Loss, and the Upper Aerodigestive Tract.Otolaryngol Clin North Am · PubMed 42810933February 1, 2027Multifunctional hydrogel assembled from phenylboronic acid-chitosan and Polygonati Rhizoma polysaccharide for accelerated radiation-combined wound healing.Colloids Surf B Biointerfaces · PubMed 42822316January 1, 2027 Accelagen Advanced Surgical Collagen Matrix, 1cc (CG-01AA); Accelagen Advanced Surgical Collagen Matrix, 2cc (CG-02AA); Accelagen Advanced Surgical Collagen Matrix, 3cc (CG-03AA); Accelagen Advanced Surgical Collagen Matrix, 5cc (CG-05AA); Accelagen Advanced Surgical Collagen Strip, 125x25x2mm (CG-125X25AA); Accelagen Advanced Surgical Collagen Strip, 250x25x2mm (CG-250X25AA)Berkeley Advanced Biomaterials · K260920October 22, 2026Collagen Wound PowderVentris Medical · K260596July 2, 2026Roosin Collagen DressingRoosin Medical Co., Ltd. · K253974June 3, 2026

PubMed dates are the journal issue date, which can run ahead of today.

6Plan of action, top 8

Key takeaway

23 actions ranked from this month’s signals; 4 high priority. The top 8 are below.

Supporting data
  • 7 Post · Publish on owned social while the topic is moving
  • 3 Prepare · Get ahead of a competitor or regulatory move
  • 3 Fix · Correct a defect or a claims risk on an owned surface
  • 7 Decide · Needs a person to decide or approve
  • 2 Optimize · Improve an existing page or profile
  • 1 Create · Make a page or asset that answers demand nobody owns yet
Action items

Work the list top down. Add any item to My plan; the full list lives on Pulse.

  1. 1
    PostHigh priority · Owner: PreHealth creative lead
    Write a post on Regenerate, don't replace

    Because breast reconstruction beyond implants is trending: 24 headlines in 3 weeks, 1.5× its earlier pace.SurvivorNet, Nov 11

  2. 2
    PostHigh priority · Owner: PreHealth creative lead
    Write a post on what an ECM scaffold is, in plain language

    Because extracellular matrix and scaffolds is trending: 10 headlines in 3 weeks, 3.3× its earlier pace.Bioengineer.org, Nov 11

  3. 3
    PostHigh priority · Owner: PreHealth creative lead
    Write a post on the wound-care path and what a 510(k) does and does not mean

    Because flowable wound matrices and 510(k) is trending: 8 headlines in 3 weeks, 1.7× its earlier pace.StreetInsider, Nov 11

  4. 4
    PostHigh priority · Owner: PreHealth creative lead
    Write a post on occupy, provoke, structure: the three mechanism classes

    Because biostimulators and regenerative aesthetics is trending: 5 headlines in 3 weeks, 2.1× its earlier pace.Trend Hunter, Nov 11

  5. 5
    PrepareMedium priority · Owner: PreHealth account lead
    Brief the team on Organogenesis’s busy week

    Because 20 headlines in 7 days, 18.3× its usual week.GuruFocus, Nov 7

  6. 6
    FixMedium priority · Owner: PreHealth account lead with client counsel
    Review 3 outcome verb passages on conexeu.com

    Because 3 passages across 3 pages; the widest, “restores”, appears on 1.Compliance findings

  7. 7
    DecideMedium priority · Owner: Client, CEO office
    Confirm which officer titles are current (CEO/CSO differ across decks and business cards)

    Because open decision D1 (P0) in the knowledge system.Knowledge system

  8. 8
    DecideMedium priority · Owner: Client counsel with CSO
    Decide whether MeshFill-era papers may be cited as CXU evidence

    Because open decision D4 (P0) in the knowledge system.Knowledge system

Not in this brief

These sources are not connected, so the brief shows no figure for them.

  • Social profiles · Followers and post engagement, read by hand. Snapshot from Conexeu Social & Search Plan, rev 1 (read Aug 20)
  • AI engines · 8 target queries across ChatGPT, Gemini, Perplexity, Claude, AI Overviews. Needs API keys
  • Google Search Console + GA4 · Queries, rankings, AI referral traffic. Needs client OAuth
  • LinkedIn + Instagram (owned) · Live followers, posts, comments. Needs client OAuth

Generated November 12, 2026 from Google News (Nov 12), conexeu.com crawl (Nov 12), PubMed (Nov 12), ClinicalTrials.gov (Nov 12), openFDA (Nov 12).